ANIXA BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-07-31 was 35.00K shares.
- ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2022-10-31 was 685.61K shares, a 5613.43% increase year-over-year.
- ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-10-31 was 12.00K shares.
- ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-07-31 was 0.00 shares.
- ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 1.64M shares, a 2832.14% increase from fiscal 2021.
- ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 56.00K shares, a 9.59% increase from fiscal 2020.
- ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 51.10K shares, a 7.35% increase from fiscal 2019.
- ANIXA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2019 was 47.60K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-07-31 | 35.00K shares 10-Q · filed 2025-09-10 | |
| 2022-10-31 | 685.61K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-01-16 | 1.64M shares 10-K · filed 2024-01-16 |
| 2021-10-31 | 12.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-01-04 | 56.00K shares 10-K · filed 2023-01-04 |
| 2021-07-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-09-01 | |
| 2020-10-31 | 51.10K shares 10-K · filed 2021-01-07 | |
| 2019-10-31 | 43.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-01-07 | 47.60K shares 10-K · filed 2021-01-07 |
| 2018-01-31 | 10.60K shares 10-Q · filed 2019-03-13 | |
| 2013-10-31 | 547.49K shares 10-Q · filed 2014-03-17 | |
| 2013-07-31 | 547.49K shares 10-Q/A · filed 2013-09-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |